Helix Biopharma to Acquire Laevoroc Immunology’s LR 09, Expanding its Immune-Oncology Portfolio
Shots:
- Helix BioPharma has entered into an asset purchase agreement with Laevoroc Immunology to acquire LR 09, expanding its immune-oncology portfolio
- As per the agreement, Helix will secure the intellectual property, inventory, agreements, and rights of LR 09 that is under preclinical investigation for treating relapse leukemia after allogeneic stem cell transplantation (SCT)
- LR 09 (ulodesine hemiglutarate) is an oral metabolic immune checkpoint inhibitor, protected through patent. It has been designated with the US FDA’s ODD in 2022
Ref: Helix BioPharma | Image: Helix BioPharma & Laevoroc Immunology
Related News:- Formosa and Medvisis Partner for Clobetasol Propionate Ophthalmic Suspension to Treat Post-Operative Inflammation and Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
